Xiao Tijun, Yan An, Tan Lifang, Zhu Hongwei, Gao Wenzhe
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Shaoyang University, Shaoyang, Hunan 422000, P.R. China.
Department of Hepatopancreatobiliary Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China.
Oncol Lett. 2024 Mar 22;27(5):226. doi: 10.3892/ol.2024.14359. eCollection 2024 May.
Elevated expression of long non-coding RNA homeobox A cluster antisense RNA 2 (lncRNA HOXA-AS2) is known to have prognostic value in various solid tumors. The present meta-analysis aimed to comprehensively quantify its prognostic significance across a wider spectrum of malignancies and to provide an updated synthesis of evidence that could refine prognostic models. To achieve this aim, multiple databases were carefully searched for lncRNA HOXA-AS2-related articles published in the past 10 years. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to demonstrate the prognostic value of lncRNA HOXA-AS2 using Stata 15.0 software. The function of lncRNA HOXA-AS2 was inferred from its associations with key clinical outcomes such as lymph node metastasis, distant metastasis, tumor stage and tumor size, which may reflect its role in tumor biology. In the present systematic review and meta-analysis of 454 patients across 7 studies, it was found that high lncRNA HOXA-AS2 expression was significantly associated with a shorter overall survival (OS) time in patients with cancer (HR=2.14; 95% CI, 1.40-3.27; P<0.001). High lncRNA HOXA-AS2 expression was also associated with lymph node metastasis [odds ratio (OR)=2.06; 95% CI, 1.07-3.99; P=0.032], distant metastasis (OR=2.11; 95% CI, 1.15-3.88; P=0.016), advanced tumor stage (OR=2.71; 95% CI, 1.50-4.89; P=0.001) and larger tumor size (OR=2.02; 95% CI, 0.86-4.78; P=0.006). However, no significant association was observed with age (OR=1.00; 95% CI, 0.63-1.59; P=0.991) or sex (OR=1.55; 95% CI, 0.72-3.34; P=0.258). In conclusion, elevated expression of lncRNA HOXA-AS2 was significantly related to poor clinical outcomes in various cancer types, such as osteosarcoma, non-small cell lung cancer and papillary thyroid carcinoma, a finding that was further confirmed by the present study. Specifically, the potential of lncRNAHOXA-AS2 as a biomarker in assessing tumor stage, metastasis risk and OS in patients was demonstrated. However, the results of the present study also indicated that the expression of lncRNA HOXA-AS2 was not significantly associated with age or sex, suggesting its role in cancer progression might be independent of these factors. This insight may direct future research to place more focus on the relationship between lncRNA HOXA-AS2 and specific cancer types and clinical characteristics.
已知长链非编码RNA同源盒A簇反义RNA 2（lncRNA HOXA-AS2）的表达升高在多种实体瘤中具有预后价值。本荟萃分析旨在全面量化其在更广泛恶性肿瘤中的预后意义，并提供可完善预后模型的最新证据综合分析。为实现这一目标，我们仔细检索了多个数据库，以查找过去10年发表的与lncRNA HOXA-AS2相关的文章。使用Stata 15.0软件计算了具有95%置信区间（CI）的风险比（HR）或优势比（OR），以证明lncRNA HOXA-AS2的预后价值。lncRNA HOXA-AS2的功能是通过其与关键临床结局（如淋巴结转移、远处转移、肿瘤分期和肿瘤大小）的关联推断出来的，这些可能反映了它在肿瘤生物学中的作用。在对7项研究中的454例患者进行的本系统评价和荟萃分析中，发现lncRNA HOXA-AS2高表达与癌症患者较短的总生存期（OS）显著相关（HR=2.14；95%CI，1.40-3.27；P<0.001）。lncRNA HOXA-AS2高表达还与淋巴结转移[优势比（OR）=2.06；95%CI，1.07-3.99；P=0.032]、远处转移（OR=2.11；95%CI，1.15-3.88；P=0.016）高级别肿瘤分期（OR=2.71；95%CI，1.50-4.89；P=0.001）和更大的肿瘤大小（OR=2.02；95%CI，0.86-4.78；P=0.006）相关。然而，未观察到与年龄（OR=1.00；95%CI，0.63-1.59；P=0.991）或性别（OR=1.55；95%CI，0.72-3.34；P=0.258）有显著关联。总之，lncRNA HOXA-AS2表达升高与多种癌症类型（如骨肉瘤、非小细胞肺癌和甲状腺乳头状癌）的不良临床结局显著相关，本研究进一步证实了这一发现。具体而言，证明了lncRNA HOXA-AS2作为评估患者肿瘤分期、转移风险和总生存期生物标志物的潜力。然而，本研究结果还表明，lncRNA HOXA-AS2的表达与年龄或性别无显著关联，表明其在癌症进展中的作用可能独立于这些因素。这一见解可能会指导未来的研究更多地关注lncRNA HOXA-AS2与特定癌症类型和临床特征之间的关系。
